1,3,4-O-acetyl-2,5-anhydro-6-deoxy-L-glucitol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,3,4-O-acetyl-2,5-anhydro-6-deoxy-L-glucitol
• 英文别名: [(2R,3S,4S,5S)-3,4-diacetyloxy-5-methyloxolan-2-yl]methyl acetate
• 化学式: C₁₂H₁₈O₇
• 分子量: 274.271
• InChiKey: FQPLIDAUFOEIJH-AQBISSITSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  L-rhamnopyranose 在 吡啶 、 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 溴 、 barium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 为溶剂， 反应 110.0h， 生成 1,3,4-O-acetyl-2,5-anhydro-6-deoxy-L-glucitol
  参考文献：
  名称：

  L-鼠李糖中的3-羟肉毒碱

  摘要：

  从鼠李糖合成毒蕈碱类似物3R-3-羟基穆斯卡因不需要保护。3S-3-羟基穆斯卡因的合成需要唯一的甲硅烷基醚保护基。可以通过δ-鼠李糖内酯的α-三氟甲磺酸酯的环收缩或通过γ-鼠李糖内酯的α-三氟甲磺酸酯的环开环来实现四氢呋喃环的有效构建。

  DOI：

  10.1016/s0040-4020(01)90162-0

文献信息

• 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
  申请人：Webber Stephen E.

  公开号：US20110275589A1

  公开（公告）日：2011-11-10

  The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.

  本发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑并[4,5-d]嘧啶-2-酮化合物及其前药。本发明还涉及使用此类化合物及其前药的治疗或预防用途，以及含有它们的制药组合物和通过给予这些化合物和前药的有效量来治疗本文所述疾病和疾病的方法。
• 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
  申请人：Webber Stephen E.

  公开号：US20120121541A1

  公开（公告）日：2012-05-17

  The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.

  本发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑和3H-噻唑[4,5-d]嘧啶-2-酮化合物及其前药。本发明还涉及使用这些化合物和前药的治疗或预防用途，以及含有它们的制药组合物，并通过给予这些化合物和前药的有效剂量来治疗本文所述的疾病和障碍的方法。
• 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof
  申请人：Webber Stephen E.

  公开号：US20130259831A1

  公开（公告）日：2013-10-03

  The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.

  该发明涉及具有免疫调节活性的3,5-二取代和3,5,7-三取代-3H-噁唑并[4,5-d]嘧啶-2-酮化合物及其前药。该发明还涉及使用这些化合物的治疗或预防用途，以及含有它们的制药组合物，以及通过给予这些化合物和前药的有效量来治疗本文所述的疾病和障碍的方法。
• US8883758B2
  申请人：——

  公开号：US8883758B2

  公开（公告）日：2014-11-11
• 3-Hydroxymuscarines from L-Rhamnose
  作者：Simon J. Mantell、Peter S. Ford、David J. Watkin、George W.J. Fleet、David Brown

  DOI：10.1016/s0040-4020(01)90162-0

  日期：1993.4

  No protection is necessary for the synthesis of the muscarine analogue 3R-3-hydroxymuscarine from L-rhamnose; a sole silyl ether protecting group is required for the synthesis of 3S-3-hydroxymuscarine. Efficient construction of the tetrahydrofuran ring can be achieved either by ring contraction of the α-triflate of δ-rhamnonolactone, or by ring opening and closing of the α-triflate of γ-rhamnonolactone

  从鼠李糖合成毒蕈碱类似物3R-3-羟基穆斯卡因不需要保护。3S-3-羟基穆斯卡因的合成需要唯一的甲硅烷基醚保护基。可以通过δ-鼠李糖内酯的α-三氟甲磺酸酯的环收缩或通过γ-鼠李糖内酯的α-三氟甲磺酸酯的环开环来实现四氢呋喃环的有效构建。